About
Curesponse’s technology represents the next step in personalized cancer medicine, advancing prediction capabilities beyond genomics to understand how cancer treatments will affect the patient’s tumor cells when they are in their native tumor.
The company developed cResponse, a test combined Genomic-Functional assay. The test starts with genomic profiling of the tumor to prioritize potential therapies. Then, together with additional therapies that were recommended by the patient’s oncologist, a short list of drugs and drug combinations is generated and functionally tested on the patient’s tumor.
The cResponse functional test preserves the original tumor composition (commonly referred to as the Tumor MicroEnvironment – TME) and its 3D structure to assess the effectiveness of all selected treatments on the tumor cells. This enables cResponse to empirically analyze the effectiveness of the recommended treatments following rapid genomic profiling with very high accuracy.
Funding history · 2 rounds · $14.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Curesponse founded and where is its headquarters located?
- Curesponse was founded in November 2017 and is headquartered in Rehovot, Israel.
- What is Curesponse's primary product or technology?
- Curesponse developed cResponse, a combined Genomic-Functional assay that tests the effectiveness of cancer treatments on a patient's tumor cells while preserving the tumor's original composition and 3D structure.
- What was Curesponse's total funding raised as of November 2021?
- As of November 2021, Curesponse had raised a total of $14 million in funding. For a full financing history, refer to startupim.
- Which investors participated in Curesponse's Series A funding round?
- Curesponse secured a $6 million Series A round in June 2020, with participation from aMoon Fund and NCL Technology Ventures.
- When did Curesponse receive its most recent funding, and what was the amount?
- Curesponse secured an additional $8 million in funding in November 2021 from undisclosed investor(s).
- What was a significant operational development for Curesponse in February 2023?
- In February 2023, Curesponse announced that Clalit Health Services, the largest Israeli HMO, would provide commercial coverage for the cResponse test.
- What clinical results did Curesponse present in May 2023?
- In May 2023, Curesponse presented positive preliminary clinical results from a multi-center UK study at the AACR Meeting in Orlando, Florida.
- Does Curesponse have an international office, and if so, where?
- Yes, Curesponse has an office located at 3 Wimpole St, London, UK.